SIGA
Supplies oral and IV TPOXX for smallpox preparedness programs.
Something off on this page? Send us feedback.
Profile
Commercial-stage health-security drug maker centered on TPOXX, an oral and IV smallpox antiviral sold mainly through U.S. and international government procurement. Revenue sits in one reportable segment and depends on BARDA contracts, stockpile deliveries, international biodefense demand, and TPOXX label expansion.
Sells oral TPOXX to the U.S. Government and international governments, and IV TPOXX to the U.S. Government for smallpox preparedness. The business is organized as one reportable segment covering TPOXX product sales and research-and-development services.
Execution centers on government procurement, BARDA contract work, stockpile delivery, and regulated product labels. U.S. use is approved for smallpox, while mpox access in the U.S. runs through CDC expanded access and some non-U.S. labels cover broader orthopox indications.
Customer concentration, BARDA funding, international biodefense demand, and approval of additional formulations shape the operating model.
Company facts
Key statistics
Year to date −51.0% · Average volume (30d) 792.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | — | $0.17 | — | — | $41.0M | — | −2.24% |
| May 7, 2026Q1 FY26 | — | −$0.05 | — | — | $6.2M | — | +1.48% |
| Mar 10, 2026Q4 FY25 | — | −$0.08 | — | — | $3.8M | — | −3.01% |
| Nov 6, 2025Q3 FY25 | — | −$0.09 | — | — | $2.6M | — | −19.95% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $81.1M | $2.6M | $3.8M | $6.2M | $41.0M | |
| Gross profit | $6.9M | $55.6M | $1.6M | $804.5K | $3.3M | $23.4M | |
| Operating income | −$2.3M | $45.7M | −$10.2M | −$9.5M | −$5.3M | $13.9M | |
| Net income | −$408.2K | $35.5M | −$6.4M | −$5.4M | −$3.5M | $12.5M | |
| Diluted EPS | −$0.01 | $0.49 | −$0.09 | −$0.08 | −$0.05 | $0.17 | |
| Gross margin | 97.8% | 68.5% | 61.8% | 21.2% | 52.9% | 57.2% | |
| Operating margin | -32.0% | 56.3% | -390.2% | -250.0% | -85.2% | 33.9% |
Fiscal years (4-quarter sums)FY21 $133.7M · FY22 $110.8M · FY23 $139.9M · FY24 $138.7M · FY25 $94.6M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $117.6M · Total debt $439.4K · Total assets $175.7M · Shareholders' equity $165.3M
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Apr 7, 2026 | Apr 7 | Apr 23 | $0.60 | special dividend |
| Apr 29, 2025 | Apr 29 | May 15 | $0.60 | special dividend |
| Mar 25, 2024 | Mar 26 | Apr 11 | $0.60 | special dividend |
| May 15, 2023 | May 16 | Jun 1 | $0.45 | special dividend |
| May 16, 2022 | May 17 | Jun 2 | $0.45 | special dividend |
Ownership
Shares outstanding 71.72M · Float 41.01M · 57.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.49M | 4.87% | 13F | May 13, 2026 |
| Dimensional Fund Advisors LP | 2.70M | 3.77% | 13F | May 7, 2026 |
| Altravue Capital, LLC | 2.43M | 3.39% | 13F | May 13, 2026 |
| Vanguard Capital Management LLC | 1.71M | 2.39% | 13F | May 15, 2026 |
| Arrowstreet Capital, Limited Partnership | 1.53M | 2.13% | 13F | May 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Emergent BioSolutions
Direct smallpox MCM peer with TEMBEXA and ACAM2000
- GeoVax Labs
Investigational second-source MVA orthopox vaccine developer
- Tonix Pharmaceuticals
Early-stage mpox/smallpox vaccine candidate with CBRN funding
- Soligenix
Broader biodefense MCM developer competing for preparedness funds
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SIGA | $3.09 | +0.65% | $219.5M | — | — | 4.1 | −49.5% |
| Emergent BioSolutions | $5.82 | −1.61% | $304.9M | — | — | 0.4 | +66.3% |
| GeoVax Labs | $0.6400 | −11.22% | $5.3M | — | — | — | — |
| Tonix Pharmaceuticals | $13.59 | +0.15% | $216.6M | — | — | 7.4 | +577.9% |
| Soligenix | $0.3733 | −0.93% | $5.6M | — | — | — | — |
| Median | — | — | 3.9 | +322.1% |